In TP53/RB1 co‐altered pancreatic adenocarcinoma (PAAD), KRAS mutations were nearly ubiquitous (88%), and a notable rate of mutations was noticed in SMAD4 (21%) (Figure 3G). This evidence concerns the gene SMAD4 and pancreatic adenocarcinoma.